OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology is 77. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	2045
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	1753
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	1586
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis	1063
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	423
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	312
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	245
Late-Breaking Abstracts	230
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	224
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	224
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	223
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	223
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	197
Cover Image	187
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	184
Retracted: M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring αMβ2 Integrin to Tumor Cells	181
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	179
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	179
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	178
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	174
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	154
Efficacy and safety of infliximab in patients with autoimmune hepatitis	149
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	146
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	144
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	141

Access to technology to support telehealth in areas without specialty care for liver disease	138
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	134
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	133
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	129
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	125
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	120
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	115
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	114
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	113
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	112
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	112
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation	112
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	111
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	110
Reply	110
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	108
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	103
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	102
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	100
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	98
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	96
Regulatory role and translational potential of CCL11 in liver fibrosis	95
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	94
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	94
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	94
	93
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	92
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	91
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	90
Genes that fit just right: Unzipping the genome of fatty liver disease	90
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	90
Therapeutic manipulation of the microbiome in liver disease	89
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?	88
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	88
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	88
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	87
Reply	86
	85
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	85
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	85
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	85
Immunobiology of primary sclerosing cholangitis	82
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	82
In vivo imaging of calcium dynamics in zebrafish hepatocytes	82
Reply: The CRAPT-M score: Robust enough for clinical practice?	81
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	81
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	81
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	80
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	78
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer	78

Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	78
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	77
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	77